Multiple myeloma preparative regimens for high-dose therapy and autologous transplantation: what's new?

被引：0
作者：
Aljitawi, Omar S. [1 ]
McGuirk, Joseph P. [1 ]
机构：
[1] Univ Kansas, Med Ctr, Blood & Marrow Transplant Program, Kansas City, KS 66103 USA
来源：
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH | 2012年 / 1卷 / 01期
关键词：
autologous; chemotherapy; multiple myeloma; preparative regimen; review; transplant; STEM-CELL TRANSPLANTATION; CONDITIONING REGIMEN; PHASE-II; RANDOMIZED-TRIAL; ALLOGENEIC TRANSPLANTATION; INTERGROUPE FRANCOPHONE; STANDARD CHEMOTHERAPY; 200 MG/M(2); MELPHALAN; CYCLOPHOSPHAMIDE;
D O I：
10.2217/CER.11.11
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
High-dose chemotherapy and autologous stem cell transplantation remains a standard procedure in relatively young and selected older patients with multiple myeloma. High-dose melphalan has remained the chemotherapeutic agent of choice based on earlier prospective randomized trials. Despite investigations involving different combinations of chemotherapeutics, radiation and novel agents with and without melphalan, none of these alternative preparative regimens have demonstrated superiority to high-dose melphalan used as a single agent in multiple published studies. In this article, we review the published literature regarding preparative regimens used in patients with multiple myeloma undergoing autologous stem cell transplantation.
引用
收藏
页码：57 / 70
页数：14
相关论文
共 50 条
  • [41] Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma
    SV Rajkumar
    R Fonseca
    MQ Lacy
    TE Witzig
    JA Lust
    PR Greipp
    TM Therneau
    RA Kyle
    MR Litzow
    MA Gertz
    Bone Marrow Transplantation, 1999, 24 : 497 - 503
  • [42] Cardiac toxicity of high-dose cyclophosphamide in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation
    Zver, Samo
    Zadnik, Vesna
    Bunc, Matjaz
    Rogel, Polona
    Cernelc, Peter
    Kozelj, Mirta
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2007, 85 (05) : 408 - 414
  • [43] A Phase lib, Multicenter, Open-Label, Safety, and Efficacy Study of High-Dose, Propylene Glycol-Free Melphalan Hydrochloride for Injection (EVOMELA) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation
    Hari, Parameswaran
    Aljitawi, Omar S.
    Arce-Lara, Carlos
    Nath, Rajneesh
    Callander, Natalie
    Bhat, Gajanan
    Allen, Lee F.
    Stockerl-Goldstein, Keith
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2015, 21 (12) : 2100 - 2105
  • [44] HIGH-DOSE CHEMORADIOTHERAPY AND AUTOLOGOUS BLOOD STEM-CELL TRANSPLANTATION IN MULTIPLE-MYELOMA
    FERMAND, JP
    CHEVRET, S
    HENNEQUIN, C
    LEVY, Y
    GEROTA, J
    BENBUNAN, M
    SELIGMANN, M
    BROUET, JC
    NOUVELLE REVUE FRANCAISE D HEMATOLOGIE, 1991, 33 (06): : 525 - 528
  • [45] High-dose chemotherapy and autologous stem cell transplantation of patients with multiple myeloma in an outpatient setting
    Katharina Lisenko
    Sandra Sauer
    Thomas Bruckner
    Gerlinde Egerer
    Hartmut Goldschmidt
    Jens Hillengass
    Johann W. Schmier
    Sofia Shah
    Mathias Witzens-Harig
    Anthony D. Ho
    Patrick Wuchter
    BMC Cancer, 17
  • [46] High-dose bendamustine and melphalan conditioning for autologous stem cell transplantation for patients with multiple myeloma
    Gomez-Arteaga, Alexandra
    Mark, Tomer M.
    Guarneri, Danielle
    Christos, Paul J.
    Gergis, Usama
    Greenberg, June D.
    Hsu, Jingmei
    Mayer, Sebastian A.
    Niesvizky, Ruben
    Pearse, Roger N.
    Phillips, Adrienne A.
    Rossi, Adriana
    Coleman, Morton
    van Besien, Koen
    Shore, Tsiporah B.
    BONE MARROW TRANSPLANTATION, 2019, 54 (12) : 2027 - 2038
  • [47] A Phase I/II Study of Escalating Doses of Bortezomib in Conjunction with High-Dose Melphalan as a Conditioning Regimen for Salvage Autologous Peripheral Blood Stem Cell Transplantation in Patients with Multiple Myeloma
    Biran, Noa
    Rowley, Scott D.
    Vesole, David H.
    Zhang, Shijia
    Donato, Michele L.
    Richter, Joshua
    Skarbnik, Alan P.
    Pecora, Andrew
    Siegel, David S.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (12) : 2165 - 2171
  • [48] Addressing the questions of tomorrow: melphalan and new combinations as conditioning regimens before autologous hematopoietic progenitor cell transplantation in multiple myeloma
    Martino, Massimo
    Olivieri, Attilio
    Offidani, Massimo
    Vigna, Ernesto
    Moscato, Tiziana
    Fedele, Roberta
    Montanari, Mauro
    Console, Giuseppe
    Gentile, Massimo
    Messina, Giuseppe
    Irrera, Giuseppe
    Morabito, Fortunato
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2013, 22 (05) : 619 - 634
  • [49] Autologous Transplantation and Maintenance Therapy in Multiple Myeloma
    Palumbo, A.
    Cavallo, F.
    Gay, F.
    Di Raimondo, F.
    Yehuda, D. B.
    Petrucci, M. T.
    Pezzatti, S.
    Caravita, T.
    Cerrato, C.
    Ribakovsky, E.
    Genuardi, M.
    Cafro, A.
    Marcatti, M.
    Catalano, L.
    Offidani, M.
    Carella, A. M.
    Zamagni, E.
    Patriarca, F.
    Musto, P.
    Evangelista, A.
    Ciccone, G.
    Omede, P.
    Crippa, C.
    Corradini, P.
    Nagler, A.
    Boccadoro, M.
    Cavo, M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (10) : 895 - 905
  • [50] High-dose chemotherapy with autologous stem cell transplantation for multiple myeloma: what predicts the outcome? Experience from a developing country
    L Kumar
    J Ghosh
    P Ganessan
    A Gupta
    R Hariprasad
    V Kochupillai
    Bone Marrow Transplantation, 2009, 43 : 481 - 489
12345